Olink Holding AB

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. The firm offers a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. It operates through the following segments: Kit and Service. The company was founded on December 13, 2018 and is headquartered in Uppsala, Sweden.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Olink Holding AB exceeds revenue goals, eyes proteomics market growth

Olink had a successful Q4 and 2022, exceeding revenue goals and showcasing innovation.
The company is poised for growth in the proteomics market with a focus on data quality.
Challenges include shifting revenue mix, expanding installations, and meeting customer demands.
Opportunities lie in developing new assays, expanding the protein library, and leveraging positive customer feedback.

Olink Holding AB reports robust Q1 growth and eyes profitability

Olink Holding AB's Q1 2023 performance reflects strong revenue growth and a focus on innovation in next-generation proteomics.
Despite challenges in certain regions and operating at a net loss, the company maintains positive cash flow and aims for profitability in 2023.
Opportunities lie in market expansion, M&A activities, and improving kit gross margins through R&D efforts.
Overall, Olink's unique positioning in the life science space and commitment to serving diverse customer needs underpin its growth potential.

Olink Holding AB (OLK) sees strong revenue growth and market optimism

Olink Holding AB (OLK) reports solid revenue growth in Q2 2023, driven by Explore revenue and scientific productivity. Despite challenges in profitability and margin improvements, the company is optimistic about the market impact of Explore HT and back-half growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.

UPPSALA, Sweden, June 02, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Signature Q100, to allow more researchers access to Olink technology and high-quality proteomics data. Olink Signature Q100 is an affordable new benchtop system designed for readout of Olink® Target and Olink® Focus protein biomarker panels.

Announcing Olink Signature Q100: facilitating access for researchers to Olink technology with a benchtop system dedicated to multiplex protein biomarker measurement

UPPSALA, Sweden, May 25, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that it will be participating in the Goldman Sachs 42nd Annual Global Healthcare Conference.

Olink to present at the Goldman Sachs 42nd Annual Global Healthcare Conference

UPPSALA, Sweden, May 20, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its financial results for the first quarter of 2021.

Olink reports first quarter 2021 financial results and issues full year 2021 guidance

UPPSALA, Sweden, April 29, 2021 (GLOBE NEWSWIRE) -- ﻿Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, today announced that it will release financial results for the first quarter of 2021 before the market open on Thursday, May 20, 2021. Company management will host a conference call to discuss financial results at 8:00 a.m. ET.

Olink to Report First Quarter 2021 Financial Results on May 20, 2021

Uppsala, Sweden, March 25, 2021 (GLOBE NEWSWIRE) -- Uppsala, Sweden – March 25, 2021 – Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of its initial public offering of 17,647,058 common shares in the form of American Depositary Shares (“ADSs”), including 4,411,764 ADSs to be sold by the selling shareholders, at a price to the public of $20.00 per ADS, with each ADS representing one common share. The gross proceeds of the offering to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately $264.7 million. The ADSs are expected to begin trading on The Nasdaq Global Market on March 25, 2021. The offering is expected to close on March 29, 2021, subject to the satisfaction of customary closing conditions.  The Company will not receive any proceeds from any sales of ADSs in the offering by the selling shareholders. In addition, the underwriters have been granted a 30-day option to purchase up to 2,647,058 additional ADSs from Knilo InvestCo AB, a selling shareholder.

Olink Holding AB (publ) Announces Pricing of Initial Public Offering

News for Olink Holding AB Stock (OLK)